In a significant move towards making cancer treatment more affordable, the GST Council's recent decision to lower the Goods and Services Tax (GST) on cancer drugs from 12% to 5% is being hailed as a major step forward. D. S. Negi, CEO of Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC), has applauded the decision, emphasizing its potential to ease the financial burden on cancer patients and their families.

"The high cost of cancer medications has been a major hurdle for many patients," Negi stated. "This reduction in GST, combined with the recent exemption from customs duty on these drugs, is aligned with our mission to provide world-class cancer care to every patient without the heavy burden of high costs."

For patients undergoing costly treatments involving drugs like Trastuzumab, Pembrolizumab, and Durvalumab, the financial strain can be overwhelming. The reduction in GST will significantly lower the cost of these life-saving medications, making cancer care more accessible to a broader population.

Negi noted that these measures reflect the government's commitment to supporting patients and advancing affordable healthcare. By reducing the financial pressure on cancer patients, especially those requiring expensive therapies, the move is expected to have a positive impact on treatment outcomes and accessibility.

"This decision is a much-needed step in ensuring that every cancer patient can access the care they need without being burdened by high costs," Negi added, underscoring the broader implications for healthcare affordability in India.